Nurix Therapeutics (NRIX) Cash from Financing Activities (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Cash from Financing Activities data on file, last reported at $20.0 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $20.0 million, up 1256.08% year-over-year; the trailing twelve-month figure through Feb 2026 was $257.1 million (down 47.04% YoY), and the FY2025 annual result was $238.6 million, down 50.86% from the prior year.
• Cash from Financing Activities retreated to $20.0 million in Q1 2026 per NRIX's latest filing, from $236.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $237.8 million in Q2 2024 and troughed at -$135000.0 in Q4 2022.
• A 5-year average of $50.9 million and a median of $1.5 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities tumbled 127.0% in 2022, then jumped 2864485.71% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$135000.0 in 2022, then jumped by 105.19% to $7000.0 in 2023, then jumped by 2864485.71% to $200.5 million in 2024, then gained by 17.7% to $236.0 million in 2025, then plunged by 91.54% to $20.0 million in 2026.
• Business Quant data shows NRIX's Cash from Financing Activities at $20.0 million in Q1 2026, $236.0 million in Q4 2025, and $1.2 million in Q3 2025.